PharmaTher Added to the North American Psychedelics Index and First
Psychedelic Exchange Traded Fund
TORONTO, September 21,
2021 -- InvestorsHub NewsWire -- PharmaTher Holdings Ltd. (the
"Company" or "PharmaTher") (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company,
is pleased to announce that the Company has been included to the
North American Psychedelics Index, (the "Index"), which is the
underlying index of the Horizons Psychedelic Stock Index Exchange
Traded Fund (the "ETF") (NEO: PSYK).
The Index is designed to provide exposure to the performance of
North American publicly-listed life sciences companies focused on
psychedelic medicines, and other companies with business activities
in the psychedelics industry. The Index is also designed to provide
diversified exposure to the psychedelics industry, at weights that
can easily and cost effectively be replicated, while at the same
time reflecting the evolution of the industry in a timely
fashion.
The ETF invests in, and
indirectly derive revenues from, companies in the psychedelics
industry engaged in legal activities involving psychedelic drugs
and substances.
PharmaTher is one of
currently twenty-four companies to have met the requirements of
listing within the ETF. The
ETF seeks to replicate the performance of the North American
Psychedelics Index, net of expenses. Rebalancing of the North
American Psychedelics Index occurs each calendar quarter.
At
those points, all stocks eligible for inclusion are generally
re-weighted by their respective float market
capitalization.
Fabio
Chianelli, Chief Executive Officer of PharmaTher, said,
"We are pleased to be
included into the first ever Psychedelic ETF as a recognition of
our accomplishments in the advancement of prescription-based
psychedelic pharmaceuticals.
The inclusion into the
Index and ETF not only broadens our investor awareness, but also
provides us with greater confidence in our business model that
focuses on the research, development and commercialization of novel
uses, formulations and delivery forms of ketamine for mental health
(i.e. Depression), rare and near-rare neurological (i.e.
Parkinson's disease, Amyotrophic
lateral sclerosis), and pain disorders.
The holdings of the
Index, the ETF and its current portfolio weights are regularly
updated and available at
www.HorizonsETFs.com/ETF/PSYK.
The ETF is managed by
Horizons ETF Management an innovative financial services company
offering one of the largest suites of exchange traded funds in
Canada. The Horizons ETFs product family includes a broadly
diversified range of solutions for investors of all experience
levels to meet their investment objectives in a variety of market
conditions. Horizons ETFs has over $19 billion of assets under
management and 95 ETFs listed on major Canadian stock exchanges.
Horizons also brought the first cannabis ETF to market in 2017 and
continues to lead the industry with ETFs in emerging
industries.
About
PharmaTher Holdings Ltd.
PharmaTher
Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is a clinical-stage
psychedelics biotech company focused on the research, development
and commercialization of novel uses, formulations and delivery
methods of psychedelics, including ketamine, to treat mental
health, neurological and pain disorders.
PharmaTher
is currently conducting an FDA approved phase 2 clinical study with
ketamine to treat Parkinson's disease and is developing novel
microneedle patches for the intradermal delivery of
psychedelics.
Learn
more at:
PharmaTher.com and
follow us on
Twitter and
LinkedIn.
For more information
about PharmaTher, please contact:
Fabio
Chianelli
Chief Executive
Officer
PharmaTher Holdings
Ltd.
Tel:
1-888-846-3171
Email:
info@pharmather.com
Website:
www.pharmather.com
Neither the Canadian Securities Exchange nor its Regulation
Services Provider have reviewed or accept responsibility for the
adequacy or accuracy of this release.
Cautionary Statement
This press release contains 'forward-looking information' within
the meaning of applicable Canadian securities legislation. These
statements relate to future events or future performance. The use
of any of the words "could", "intend", "expect", "believe", "will",
"projected", "estimated", "potential", "aim" and similar
expressions and statements relating to matters that are not
historical facts are intended to identify forward-looking
information and are based on PharmaTher Holdings Ltd. (the
"Company") current belief or assumptions as to the outcome and
timing of such future events. Forward-looking information is based
on reasonable assumptions that have been made by the Company at the
date of the information and is subject to known and unknown risks,
uncertainties, and other factors that may cause actual results or
events to differ materially from those anticipated in the
forward-looking information. Given these risks, uncertainties and
assumptions, you should not unduly rely on these forward-looking
statements. The forward-looking information contained in this press
release is made as of the date hereof, and Company is not obligated
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise, except as
required by applicable securities laws. The foregoing statements
expressly qualify any forward-looking information contained herein.
Factors that could cause actual results to differ materially from
those anticipated in these forward-looking statements are described
under the caption "Risk Factors" in Company's management's
discussion and analysis for the period
of May 31, 2021 ("MD&A"), dated September 7, 2021,
which is available on the Company's profile at
www.sedar.com.
This news release does not constitute an offer to sell or the
solicitation of an offer to buy, and shall not constitute an offer,
solicitation or sale in any state, province, territory or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state, province, territory or
jurisdiction.
